生物制剂前治疗历程对银屑病生物制剂药物生存的影响:全国队列研究
该研究基于丹麦全国登记数据,纳入2010年至2021年间首次启用生物制剂治疗的2496例银屑病患者,随访最长5年。采用三种定义评估生物制剂前传统系统治疗历程的复杂性,发现三种定义均不影响后续生物制剂的药物生存率。
要点
- 传统系统治疗历程的复杂性不影响后续生物制剂的药物生存。
- 在疾病控制充分的前提下,传统系统治疗不负面影响生物制剂生存。
- 研究基于丹麦全国登记数据,随访最长5年。
核心结论
- 三种用于评估生物制剂前治疗历程复杂性的暴露定义均未显示影响药物生存。
研究设计与样本
- 基于丹麦全国登记数据的纵向队列研究,纳入2010年1月1日至2021年6月30日首次启用生物制剂治疗的银屑病患者,最长随访5年。
主要发现
- 共纳入2496例患者,平均起始生物制剂年龄43.6岁(SD 15.2岁),男性占62.9%。
- 随访5477患者年期间,1953例(78.2%)达到主要终点停药。
- Log-rank检验显示,三种治疗历程复杂性定义下继续治疗的概率均无差异。
临床怎么用
- 在疾病控制充分的前提下,不应因传统系统治疗历程复杂而限制后续生物制剂的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unknown whether the pre-biologic treatment journey affects subsequent biologic drug survival. OBJECTIVE: To examine the potential impact of a complex treatment journey on subsequent biologic drug survival in patients with psoriasis. METHODS: The study utilized longitudinal data from Danish national registries and included all patients who, for the first time, initiated a biological treatment for psoriasis. Maximum follow-up was 5 years and patients were included from 1 January 2010 to 30 June 2021. The study used three definitions of exposure to a complex treatment journey and the following conventional systemic treatments: acitretin, cyclosporine, dimethyl fumarate and methotrexate. The first definition was the cumulative number of treatment series. The second definition comprised the number of unique treatments. The third definition was time from the first conventional systemic treatment to biological therapy. Drug survival for the three definitions were illustrated using Kaplan-Meier curves and compared using log-rank test. The sensitivity analysis largely confirmed these findings by grouping patients according to pharmacotherapy. RESULTS: A total of 2496 patients were included in the study, with 1380 (55.3%) receiving adalimumab, 608 (24.4%) receiving ustekinumab, 271 (10.9%) receiving secukinumab, 166 (6.7%) receiving etanercept and 71 (2.8%) receiving infliximab. The mean age at initiation of biologics was 43.6 years (standard deviation (SD) 15.2 years), and most patients were male (62.9%). During the follow-up of 5477 patient years, 1953 patients (78.2%) reached the main endpoint of discontinuation. Using a log-rank test, the probability of remaining on treatment was unaffected by the three definitions of complexity of the treatment journey. CONCLUSION: None of the three exposures used to assess the complexity of the pre-biologic treatment journey appeared to impact drug survival. As long as patients experience adequate disease control, these results suggest that conventional systemic treatment do not negatively impact the drug survival of subsequent biologics.
引用
- Thein D, Nielsen ML, Maul JT, et al. Impact of the pre-biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study. J Eur Acad Dermatol Venereol. 2024. PMID: 39051535. doi:10.1111/jdv.20259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。